Nonsteroidal anti-inflammatory drugs

Foye's Principles of Medicinal Chemistry: Seventh Edition

Volumn , Issue , 2012, Pages 987-1044

  Borne, Ronald ^a   Levi, Mark ^b   Wilson, Norman ^c  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84946034247     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Borne RF. Non-steroidal anti-inflammatory agents, antipyretics, and uricosuric agents. In: Verderame M, ed. Handbook of Cardiovascular and Anti- Inflammatory Agents. Boca Raton, FL: CRC Press, 1986:27-104.
2. Klippel JH, Stone JH, Crofford LJ, et al., eds. Primer on the Rheumatic Diseases, 13th Ed. New York: Springer-Verlag, 2008.
3. Hootman J, Bolen J, Helmick C, et al. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation-United States, 2003-2005. Morbid Mortal Wkly Rep 2006;55:1089-1092.
4. Hootman JM, Helmick CG. Projections of U.S. prevalence of arthritis and associated activity limitations. Arthritis Rheum 2006;54:266-329.
5. Hamor GH. Non-steroidal anti-inflammatory drugs. In: Foye WO, ed. Principles of Medicinal Chemistry, 3rd Ed. Philadelphia, PA: Lea & Febiger, 1989:503-530.
6. Walport M. Complement. In: Roitt IM, Brostoff J, Male DK, eds. Immunology, 2nd Ed. St. Louis, MO: C.V. Mosby Co., 1989.
7. Kinoshita T. Biology of complement: the overture. Immunol Today 1991;12:291-295.
8. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991;12:322-326.
9. Frank MM, Hester CG. Complement and arthritis: another step in understanding. Arthritis Res Ther 2008;10:104-110.
10. Shen TY. Proc. Int. Symp. Milan, 1964. In: Grattini S, Dukes MNG, eds. Excerpta Medica, Amsterdam, 1965;18.
11. Shen TY. Anti-inflammatory agents. Top Med Chem 1967;1:29-38.
12. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.
13. Gund P, Shen TY. A model for the prostaglandin synthetase cyclooxygenation site and its inhibition by antiinflammatory arylacetic acids. J Med Chem 1977;20:1146-1152.
14. Kurzrok R, Lieb C. Biochemical studies of human semen II the action of semen on the human uterus. Proc Soc Exptl Biol NY 1931;28:268.
15. Goldblatt MW. Properties of human seminal plasma. J Physiol (London) 1935;84:208-218.
16. von Euler US. The specific vasodilating and plain muscle-stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol (London) 1936;88:213-234.
17. Bergstrom S, Samuelsson B. The prostaglandins. Endeavour 1968;27:109-113.
18. Campbell WB. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Gilman AG, Rall TW, Nies AS, et al., eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 8th Ed. New York: Pergamon Press, 1990:600-601.
19. Miyamoto T, Ogino N, Yaamamoto S, et al. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 1976;251:2629-2632.
20. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88:2692-2696.
21. Hla T, Nielson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992;89:7384-7388.
22. Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054.
23. Kennedy B, Chan C-C, Culp S, et al. Cloning expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem Biophys Res Commun 1993;197:494-500.
24. Kujubu DA, Fletcher BS, Varnum C, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-12872.
25. Chandrasekharan NV, Dai H, Roos K, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-13931.
26. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem 2007;50:1425-1440.
27. Roche VF. A receptor-grounded approach to teaching nonsteroidal antiinflammatory drug chemistry and structure-activity relationships. Am J Pharm Educ 2009;73:143-149.
28. Flower RJ. The development of COX2 inhibitors. Nat Rev Drug Discov 2003;2:179-191.
29. Chang HW, Jahng Y. Selective cyclooxygenase-2 inhibitors as anti-inflammatory agents. Korean J Med Chem 1998;8:48-79.
30. Vane JR, Bakhle YS, Botting YM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
31. Botting JH. Nonsteroidal anti-inflammatory agents. Drugs Today 1999;35:225-235.
32. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004;103:147-166.
33. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002;68-69:535-556.
34. Smyth EM, Burke A, Fitzgerald GA. Lipid-derived autocoids: eicosanoids and platelet-activating factor. In: Brunton LI, Lazo JS, Parker KI, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 11th Ed. New York: Pergamon Press, 2006:653-670.
35. Okazaki T, Sagawa N, Okita, JR, et al. Diacylglycerol metabolism and arachidonic acid release in human fetal membranes and decidua vera. J Biol Chem 1981;256:7316-7321.
36. Clark WG. Mechanisms of antipyretic action. Gen Pharmacol 1979;10:71-77.
37. Hersh EV, Lally ET, Moore PA. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? Curr Med Res Opin 2005;21:1217-1226.
38. Qin N, Zhang SP, Reitz TL, et al. Cloning, expression, and functional characterization of human COX-1 splicing variants: evidence for intron-1 retention. J Pharmacol Exp Ther 2005;315:1298-1305.
39. Nurmi JT, Puolakkainen PA, Rautonen NE. Intro-1 retaining cyclooxygenase- 1 splice variant is induced by osmotic stress in human intestinal epithelial cells. Prostaglandins Leukot Essent Fatty Acids 2005:73:343-350.
40. Snipes JA, Kis B, Shelness GS, et al. Cloning and characterization of cyclooxygenase- 1b (putative cyclooxygenase-3) in rat. J Pharmacol Exp Ther 2005;313:668-676.
41. Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005;315:1-7.
42. Hamza M, Dione RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2005;2:1-14.
43. Fowler CJ, Stenström A, Tiger G. Ibuprofen inhibits the metabolism of the endogenous cannabimimetic anandamide. Pharmacol Toxicol 1997;80:103-107.
44. Holt S, Paylor B, Boldrup L, et al. Inhibition of fatty acid amide hydrolase, a key cannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin. Eur J Pharmacol 2007;565:26-32.
45. Schlosberg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009;11:39-44.
46. Hogestatt ED, Jonsson BAG, Ermund A, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolasedependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005;280:31405-31412.
47. Onnis V, Congiu C, Bjorklund E, et al. Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors. J Med Chem 2010;53:2286-2298.
48. Smith PA, Selley DE, Sim-Selley LJ, et al. Low dose combination of morphine and D9-tetrahydrocaannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 2007;571:129-137.
49. Ahn DK, Choi HS, Yeo SP, et al. Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. Pain 2007;132:23-32.
50. Fowler CJ, Holt S, Nilsson, et al. The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 2005;81:248-262.
51. Bancos S, Bernard MP, Topham DL, et al. Ibuprofen and other widely used non-steroidal antiinflammatory drugs inhibit antibody production in human cells. Cell Immunol 2009;258:18-28.
52. Vann RE, Cook CD, Martin BR, et al. Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther 2007;320:678-686.
53. Klein TW, Newton CA. Therapeutic potential of cannabinoid-based drugs. Adv Exp Med Biol 2007;601:395-413.
54. Chiang N, Serhaan CN, Dahlen S-E, et al. The lipoxin receptor ALX: potent-ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006;58:463-487.
55. Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: an update. Biochim Biophys Acta 2010;180:1260-1267.
56. Zurier RB, Sun Y-P, Kerri L, et al. Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J 2009;23:1503-1509.
57. Burnstein SH, Zurier RB. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 2009;11:109-118.
58. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/ acetaminophen. Prostaglandins Leukot Essent Fatty Acids 2005;72:85-87.
59. Kis B, Snipes JA, Simandle SA, et al. Acetaminophen-sensitive prostaglandin production in rat cerebral endothelial cells. Am J Physiol 2005;288:R897-R902.
60. Graham GC, Scott RF. Mechanism of action of paracetamol. Am J Ther 2005;12:46.
61. Kunkel DB. Emergency Medicine. Basel: Geigy Pharmaceuticals, July 15, 1985.
62. Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther 1973;187:185-194.
63. Sinclair J, Jeffery E, Wrighton S, et al. Alcohol-mediated increase in acetaminophen hepatotoxicity. Biochem Pharmacol 1998;55:1557-1565.
64. Calder IC, Creek MJ, Williams PJ, et al. N-Hydroxylation of p-acetophenetidide as a factor in nephrotoxicity. J Med Chem 1973;16:499-502.
65. Buckpitt AR, Rollins DE, Mitchell JR. Varying effects of sulfhydryl nucleophiles on acetaminophen oxidation and sulfhydryl adduct formation. Biochem Pharmacol 1979;28:2941-2946.
66. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New Engl J Med 1988;319:1557-1562.
67. Hennekens CH, Buting JE. Final report on the aspirin component of the ongoing physicians' health study. New Engl J Med 1989;321:129-135.
68. Gossel TA. Aspirin's role in reducing cardiac mortality. U.S. Pharmacist 1988;13:34.
69. Thun MJ, Namboodiri MM, Heath CW. Unsuccessful emergency medical resuscitation: are continued efforts in the emergency department justified? New Engl J Med 1991;325:1393-1398.
70. Kalgutkar AS, Crews BC, Rowlinson SW, et al. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science 1998;280:1268-1270.
71. Davison C. Salicylate metabolism in man. Ann N Y Acad Sci 1971;179:249-268.
72. Paulus HE, Whitehouse MW. Some relevant clinical conditions and the available therapy. In: Rubin AA, ed. Search for New Drugs, Vol. 6. New York: Marcel Dekker, 1972:11-40.
73. Shen TY, Ellis RL, Windholz TB, et al. Non-steroid anti-inflammatory agents. J Am Chem Soc 1963;85:488-489.
74. Shen TY, Witzel BE, Jones H, et al. U.S. Patent 3,654,349,971. Chem Abstr 1971;74:141379v.
75. Carson JR, McKinstry DN, Wong S. 5-Benzoyl-1-methylpyrrol-2-acetic acids as anti-inflammatory agents. J Med Chem 1971;14:646-647.
76. Sallman A, Pfister R. Ger. Patent 1,815,802. 1969. Chem Abstr 1970;72:12385d.
77. Poon GK, Chen Q, Teffera Y, et al. Bioactivation of diclofenac via benzoquinone imine intermediates: identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab Disp 2001;29:1608-1613.
78. Demerson CA, Humber LG, Dobson TA, et al. Chemistry and anti-inflammatory activities of prodolic acid and related 1,3,4,9-tetrahydropyrano[3,4,-b] indole-1-alkanoic acids. J Med Chem 1975;18:189-191.
79. Demerson CA, Humber LG, Phillip AH, et al. Etodolic acid and related compounds. Chemistry and anti-inflammatory actions of some potent di- and trisubstituted 1,3,4,9-tetrahydropyrano [3,4-b]indole-1-acetic acids. J Med Chem 1976;19:391-395.
80. Goudie AC, Gaster LM, Lake AW, et al. 4-(6-Methoxy-2-naphthyl)butan-2-one and related analogues, a novel structural class of anti-inflammatory compounds. J Med Chem 1978;21:1260-1264.
81. Nicholson JS, Adams SS. Brit. Patent. 971,700. Chem Abstr 1964;61:14591d.
82. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids: a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693-704.
83. Marshall WS. French Patent 2,015,728. 1970. Chem Abstr 1971;75:48707m.
84. Rubin A, Warrick P, Wolen RL, et al. Physiological disposition of fenoprofen in man. III. Metabolism and protein binding of fenoprofen. J Pharmacol Exp Ther 1972;183:449-457.
85. Farge D, Messer MN, Moutonnier C. U.S. Patent 3,641,127. 1972. Chem Abstr 1974;81:50040f.
86. Ueno K, Kubo S, Tagawa H, et al. 6,11-Dihydro-11-oxodibenz[b,e] oxepinacetic acids with potent antiinflammatory activity. J Med Chem 1976;19:941-946.
87. Harrison IT, Lewis B, Nelson P, et al. Nonsteroidal antiinflammatory agents. I. 6-Substituted 2-naphthylacetic acids. J Med Chem 1970;13:203-205.
88. Janssen PAJ, Van Deale GHP, Boey JM. Ger. Patent 2,353,375. 1974. Chem Abstr 1973;79:104952j.
89. Adams SS, Bernard J, Nicholson JS, et al. U.S. Patent 3,755,427. 1975. Chem Abstr 1974;81:49433e.
90. Menzel-Soglowek S, Geisslinger G, Beck WS, et al. Variability of inversion of (R)-flurbiprofen in different species. J Pharm Sci 1992;81:888-891.
91. Geisslinger G, Lotsch J, Menzel S, et al. Stereoselective disposition of flurbiprofen in healthy subjects following administration of single enantiomers. Br J Clin Pharmacol 1994;37:392-394.
92. Wechter WJ, Kantoci D, Murray ED Jr, et al. R-Flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997;57:4316-4324.
93. Morihara T, Chu T, Ubeda O, et al. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 2002;83:1009-1012.
94. Davies NM. Clinical pharmacokinetics of oxaprozin. Clin Phrmacokinetics 1998;35:425-436.
95. Scherrer RA. Introduction to the chemistry of antiinflammatory and antiarthritic agents. In: Scherrer RA, Whitehouse MW, eds. Anti-Inflammatory Agents, Vol. 1. New York: Academic Press, 1974:35-55.
96. Scherrer RA. Aryl- and heteroarylcarboxylic acids. In: Scherrer RA, Whitehouse MW, eds. Anti-Inflammatory Agents, Vol. 1. New York: Academic Press, 1974:56-74.
97. Winder CV, Wax J, Scotti L, et al. Anti-inflammatory, antipyretic and antinociceptive properties of N-(2,3-xylyl) anthranilic acid (mefenamic acid). J Pharmacol Exp Ther 1962;138:405-413.
98. Appleton RA, Brown K. Conformational requirements at the prostaglandin cyclooxygenase receptor site: a template for designing non-steroidal antiinflammatory drugs. Prostaglandins 1979;18:29-34.
99. Carty TJ, Stevens JS, Lombardino JG, et al. Piroxicam, a structurally novel antiinflammatory compound. Mode of prostaglandin synthesis inhibition. Prostaglandins 1980;19:671-682.
100. Lombardino JG, Wiseman EH. Piroxicam and other antiinflammatory oxicams. Med Res Rev 1982;2:127-152.
101. Lombardino JG, Wiseman EH, Chiaini J. Potent anti-inflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide. J Med Chem 1973;16:493-496.
102. Black WC. Selective cyclooxygenase-2 inhibitors. Ann Rep Med Chem 2004;39:125-138.
103. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568.
104. Chan CC, Boyce S, Brideau C, et al. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551-560.
105. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
106. Aw T-J, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:1-7.
107. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-1711.
108. Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707-1709.
109. Dogne J-M, Supuran CT, Pratico D. Adverse cardiovascular effects of the coxibs. J Med Chem 2005;48:2251-2257.
110. Szewczuk LM, Penning TM. Mechanism-based inactivation of COX-1 by red wine m-hydroquinones. A structure-activity relationship study. J Nat Prod 2004;67:1777-1782.
111. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase- mediated inactivator of COX-1 but not COX-2-A Mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem 2004;279: 22727-22737.
112. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997;40:1347-1365.
113. McEvoy GK, ed. American Hospital Formulary Service Drug Information 2011. STAT!Ref Online Electronic Medical Library. Available at: http:// www.statref.com/. Accessed January 14, 2011.
114. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five year experience from the FINRACo study. Arthr Rheumat 2004;50:2072-2081.
115. Youn HS, Lee JY, Saitoh SI, et al. Auranofin, as an antirheumatic gold compound suppresses LPS-induced homodimerization of TLR4. Biochem Biophys Res Comun 2006;350:866-871.
116. Yang JP, Merin JP, Nakano T, et al. Inhibition of the DNA binding activity of NF-kappa B by gold compounds in vitro. FEBS Lett 1995;321:89-96.
117. Bratt J, Belcher J, Vercellotti GM, et al. Effects of antirheutmatic gold salts on NF-kB mobilization and tumor necrosis factor-alpha (TNF-a)-induced neutrophil-dependent cytotoxicity for human endothelial cells. Clin Exp Immunol 2000;120:79-84.
118. Weber SM., Levitz SM. Chloroquine interferes with lipopolysaccharideinduced TNF- gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-1540.
119. Flanagan ME, Blumenkopf TA, Brissette WH et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53:8468-8484.
120. Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release. J Immunol 1996;156:1937-1941.
121. Gadangi P, Longaker M, Naime D, et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release. J Immunol 1996;156:1937-1941.
122. Naguwa SM. Tumor necrosis factor inhibitor therapy for rheumatoid arthritis. NY Acad Sci 2005;1051:709-715.
123. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-966.
124. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-1359.
125. King KM, Younes A. Rituximab; review and clinical applications focusing on non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2001;1:177-186.
126. Kaushik VV, Moots RJ. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 2005;5:601-606.
127. McCluggage LK, Scholtz JM. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2010;44:135-144.
128. Shealy D, Cai A, Nesspor T, et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNF-a. Ann Rheum Dis 2007;66(Suppl 2):151.
129. Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-632.
130. Kaine JL. Abatacept for the treatment of rheumatoid arthritis. Curr Ther Res 2007;68:379-399.
131. Zhang P, Li J, Han Y, et al. Traditional Chinese medicine in the treatment of rheumatoid arthritis. Rheumatol Int. 2010;30:713-718.
132. Centers for Disease Control and Prevention. Gout. Available at: http://www.cdc.gov/arthritis/basics/gout.htm.
133. Pfister R, Häflinger F. über derivate und analoġe de phenylbutazoins IV analoġe mit schwefelhaltiġen seitenkitten. Helv Chim Acta 1961;44: 232-237.
134. Robins RK. Potential purine antagonist. I. Synthesis of some 4,6-substituted pyrazolo[3,4-d] pyrimidines. J Am Chem Soc 1956;78:784-790.
135. Stamp LK, O'Donnell JL, Chapman PT. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J 2007;37:258-266.
136. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40: 21187-21194.
137. Sorbera LA, Casta FR, Rabasseda X, et al. Synthesis of TMX-67. Drugs Fut 2001;26:32.
138. Grabowski BA, Khosravan R, Vernillet L, et al. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J Clin Pharmacol 2011;51:189-201.
139. Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica 2008;38:496-510.
140. Avena-Woods C, Hilas O. Febuxostat (Uloric), a new treatment option for gout. Pharm Therapeut 2010;35:82-85.